Margarita Gudkova

Margarita Gudkova

Auto-generated profile, based on publicly available information

Margarita Gudkova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2018 in Molecules
Verified
Journal Article
Open access
PDF file
SSSvetlana Semina
Svetlana Semina
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
AVAnna Vnukova
Anna Vnukova
DBDmitry Bagrov
Dmitry Bagrov
EEEvgeniy G. Evtushenko
Evgeniy G. Evtushenko
Mikhail Krasil’nikovMikhail Krasil’nikov
Mikhail Krasil’nikov
Exosomes are small vesicles which are produced by the cells and released into the surrounding space. They can transfer biomolecules into recipient cells. The main goal of the work was to study the exosome involvement in the cell transfer of hormonal resistance. The experiments were performed on in vitro cultured estrogen-dependent MCF-7 breast cancer cells and MCF-7 sublines resistant to SERM tamoxifen and/or biguanide metformin, which exerts its anti-proliferative effect, at least in a part, via the suppression of estrogen machinery. The exosomes were purified by differential ultracentrifugation, cell response to tamoxifen was determined by MTT test, and the level and activity of signaling proteins were determined by Western blot and reporter analysis. We found that the treatment of the parent MCF-7 cells with exosomes from the resistant cells within 14 days lead to the partial resistance of the MCF-7 cells to antiestrogen drugs. The primary resistant cells and the cells with the exosome-induced resistance were characterized with these common features: decrease in ERα activity and parallel activation of Akt and AP-1, NF-κB, and SNAIL1 transcriptional factors. In general, we evaluate the established results as the evidence of the possible exosome involvement in the transferring of the hormone/metformin resistance in breast cancer cells.

3 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
OAOlga Andreeva
Olga Andreeva
DSDanila Sorokin
Danila Sorokin
EMEkaterina Mikhaevich
Ekaterina Mikhaevich
IBIrina Bure
Irina Bure
YSYuri Shchegolev
Yuri Shchegolev
Mikhail Krasil’nikovMikhail Krasil’nikov
Mikhail Krasil’nikov
Hormone therapy is one of the most effective breast cancer treatments, however, its application is limited by the progression of hormonal resistance, both primary or acquired. The development of hormonal resistance is caused either by an irreversible block of hormonal signalling (suppression of the activity or synthesis of hormone receptors), or by activation of oestrogen-independent signalling pathways. Recently the effect of exosome-mediated intercellular transfer of hormonal resistance was revealed, however, the molecular mechanism of this effect is still unknown. Here, the role of exosomal miRNAs (microRNAs) in the transferring of hormonal resistance in breast cancer cells has been studied. The methods used in the work include extraction, purification and RNAseq of miRNAs, transfection of miRNA mimetics, immunoblotting, reporter analysis and the MTT test. Using MCF7 breast cancer cells and MCF7/T tamoxifen-resistant sub-line, we have found that some miRNAs, suppressors of oestrogen receptor signalling, are overexpressed in the exosomes of the resistant breast cancer cells. The multiple (but not single) transfection of one of the identified miRNA, miR-181a-2, into oestrogen-dependent MCF7 cells induced the irreversible tamoxifen resistance associated with the continuous block of the oestrogen receptor signalling and the activation of PI3K/Akt pathway. We suppose that the miRNAs-ERα suppressors may act as trigger agents inducing the block of oestrogen receptor signalling and breast cancer cell transition to an aggressive oestrogen-independent state.

1 October 2020 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
YSYuri Shchegolev
Yuri Shchegolev
DSDanila Sorokin
Danila Sorokin
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
ASAlexey Shunaev
Alexey Shunaev
OAOlga Andreeva
Olga Andreeva
Mikhail Krasil’nikovMikhail Krasil’nikov
Mikhail Krasil’nikov

25 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
OAOlga Andreeva
Olga Andreeva
YSYuri Shchegolev
Yuri Shchegolev
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
EMEkaterina Mikhaevich
Ekaterina Mikhaevich
DSDanila Sorokin
Danila Sorokin
Mikhail Krasil’nikovMikhail Krasil’nikov
Mikhail Krasil’nikov
Exosomes are the small vesicles that are secreted by different types of normal and tumour cells and can incorporate and transfer their cargo to the recipient cells. The main goal of the present work was to study the tumour exosomes’ ability to accumulate the parent mutant DNA or RNA transcripts with their following transfer to the surrounding cells. The experiments were performed on the MCF7 breast cancer cells that are characterized by the unique coding mutation in the PIK3CA gene. Using two independent methods, Sanger sequencing and allele-specific real-time PCR, we revealed the presence of the fragments of the mutant DNA and RNA transcripts in the exosomes secreted by the MCF7 cells. Furthermore, we demonstrated the MCF7 exosomes’ ability to incorporate into the heterologous MDA-MB-231 breast cancer cells supporting the possible transferring of the exosomal cargo into the recipient cells. Sanger sequencing of the DNA from MDA-MB-231 cells (originally bearing a wild type of PIK3CA) treated with MCF7 exosomes showed no detectable amount of mutant DNA or RNA; however, using allele-specific real-time PCR, we revealed a minor signal from amplification of a mutant allele, showing a slight increase of mutant DNA in the exosome-treated MDA-MB-231 cells. The results demonstrate the exosome-mediated secretion of the fragments of mutant DNA and mRNA by the cancer cells and the exosomes’ ability to transfer their cargo into the heterologous cells.

1 December 2005 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
IKI. A. Kudryavtsev
I. A. Kudryavtsev
MGM. V. Gudkova
M. V. Gudkova
OPO. M. Pavlova
O. M. Pavlova
AOA. E. Oreshkin
A. E. Oreshkin
NMN. V. Myasishcheva
N. V. Myasishcheva

21 August 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DSDanila Sorokin
Danila Sorokin
YSYuri Shchegolev
Yuri Shchegolev
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
OROxana Ryabaya
Oxana Ryabaya
MGMargarita Gudkova
Margarita Gudkova
Mikhail Krasil’nikovMikhail Krasil’nikov
Mikhail Krasil’nikov
The phenomenon of the primary or acquired resistance of cancer cells to antitumor drugs is among the key problems of oncology. For breast cancer, the phenomenon of the resistance to hormonal or target therapy may be based on the numerous mechanisms including the loss or mutation of estrogen receptor, alterations of antiapoptotic pathways, overexpression of growth-related signaling proteins, etc. The perspective approaches for overcoming the resistance may be based on the usage of compounds such as inhibitors of the cell energetic metabolism. Among the latter, the antidiabetic drug metformin exerts antitumor activity via the activation of AMPK and the subsequent inhibition of mTOR signaling. The experiments were performed on the ERα-positive MCF-7 breast cancer cells, the MCF-7 sublines resistant to tamoxifen (MCF-7/T) and rapamycin (MCF-7/Rap), and on triple-negative MDA-MB-231 breast cancer cells. We have demonstrated metformin’s ability to enhance the cytostatic activity of the tamoxifen and rapamycin on both parent MCF-7 cells and MCF-7-resistant derivates mediated via the suppression of mTOR signaling and growth-related transcriptional factors. The cooperative effect of metformin and tested drugs was realized in an estrogen-independent manner, and, in the case of tamoxifen, was associated with the activation of apoptotic cell death. Similarly, the stimulation of apoptosis under metformin/tamoxifen co-treatment was shown to occur in the MCF-7 cells after steroid depletion as well as in the ERα-negative MDA-MB-231 cells. We conclude that metformin co-treatment may be used for the increase and partial restoration of the cancer cell sensitivity to hormonal and target drugs. Moreover, the combination of metformin with tamoxifen induces the apoptotic death in the ERα-negative breast cancer cells opening the additional perspectives in the treatment of estrogen-independent breast tumors.